Lucid Diagnostics Inc Cash Flow Conversion Efficiency
Lucid Diagnostics Inc cash flow conversion efficiency. Based on the latest financial reports, Lucid Diagnostics Inc (LUCD) has a cash flow conversion efficiency ratio of -1.034x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.30 Million) by net assets ($10.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lucid Diagnostics Inc (2018–2025)
Cash flow conversion efficiency of Lucid Diagnostics Inc from 2018 to 2025. This chart illustrates how Lucid Diagnostics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Lucid Diagnostics Inc for real-time trading data and today's change.
Lucid Diagnostics Inc Cash Flow Conversion Ratio Explained
Lucid Diagnostics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lucid Diagnostics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lucid Diagnostics Inc ranked by their cash flow conversion efficiency. Also see how much is Lucid Diagnostics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Blue Cap AG
XETRA:B7E
|
0.124x |
|
FIH Mobile Limited
F:FW3
|
-0.215x |
|
Samsung Pharm
KO:001360
|
-0.013x |
|
Dallasnews Corp
NASDAQ:DALN
|
-0.266x |
|
LOT VACUUM Co. Ltd
KQ:083310
|
0.030x |
|
Y-Entec Co. Ltd
KQ:067900
|
0.026x |
|
Articore Group Ltd
AU:ATG
|
-0.437x |
|
Qua Granite Hayal Yapi ve Urunleri Sanayi Ticaret AS
IS:QUAGR
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Lucid Diagnostics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Lucid Diagnostics Inc from 2018 to 2025. Review financial flexibility index of Lucid Diagnostics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.94 Million | $-46.48 Million | -4.251x | +48.09% |
| 2024-12-31 | $5.39 Million | $-44.14 Million | -8.188x | -157.66% |
| 2023-12-31 | $-2.31 Million | $-32.82 Million | 14.200x | +1202.49% |
| 2022-12-31 | $23.05 Million | $-29.68 Million | -1.288x | -299.05% |
| 2021-12-31 | $54.74 Million | $-17.67 Million | -0.323x | -177.52% |
| 2020-12-31 | $-13.52 Million | $-5.63 Million | 0.416x | -6.38% |
| 2019-12-31 | $-5.31 Million | $-2.36 Million | 0.445x | +177.13% |
| 2018-12-31 | $-1.06 Million | $-170.55K | 0.160x | -- |
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with th… Read more